Sylvère Bastien from the École normale supérieure de Lyon unveils biomarkers for the diagnosis of bacterial co-infections

Sylvère Bastien from the École normale supérieure de Lyon has unlocked the scientific barrier of bacterial co-infections by developing innovative biomarkers. This research, supported by the ABES/STAR network, offers promising clinical prospects for diagnosis and treatment, particularly for vulnerable patients such as those with cystic fibrosis.

Bacterial co-infections, particularly those caused by Staphylococcus aureus and Pseudomonas aeruginosa, pose a major challenge for public health, especially in patients with cystic fibrosis. These infections can worsen patients' health, highlighting the need for in-depth research on their complex interactions and clinical impacts.

Sylvère Bastien's thesis uses 'omic' approaches to analyze the underlying mechanisms of co-infections. Preliminary results show that these co-infections modify the expression of virulence and resistance genes, which could transform the strategies for diagnosing and treating bacterial infections.

The implications of this research are strategic for health policymakers. The development of biomarkers for the diagnosis of bacterial co-infections represents a significant market opportunity, especially in light of the increasing cases of antibiotic resistance. It is crucial to act quickly to support these innovations.

« « Our studies show that co-infections modify the expression of virulence genes, which could have major implications for the treatment of patients with cystic fibrosis. » — Sylvère Bastien »

« « Sylvère Bastien's research paves the way for innovative solutions for the diagnosis of co-infections, a crucial issue for public health in West Africa. » — Lektaris team »